Thrombate Iii (antithrombin III (human plasma derived))
Plasma Proteins Which Facilitate Anticoagulation Intravenous Vial (EA)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Anticoagulant; naturally occurring plasma thrombin inhibitor.
Neutralizes serine proteinases such as thrombin, plasmin, and activated coagulation factors IX, X, XI, and XII.
Principally neutralizes thrombin and activated coagulation factor X (Xa). Neutralization of factor Xa prevents thrombin generation (e.g., decreased formation of prothrombin fragment 1.2 (F1 and F2)). Neutralization of thrombin prevents conversion of fibrinogen to fibrin.
Slowly and irreversibly complexes stoichiometrically with these coagulation factors; such reactions are rapid in presence of endogenous heparin-like proteoglycans or exogenous heparin.
Inhibits thrombus formation and may prevent extension of existing thrombi.
Generic name: antithrombin III (human plasma derived)
Drug class: Plasma Proteins Which Facilitate Anticoagulation
Therapeutic class: Hematological Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Thrombate Iii
Indications
The following indications are listed for Thrombate Iii:
- Antithrombin Iii Deficiency
Also known as: Atiii Deficiency.
Dosing
Potency expressed in international units (units) as tested against activity of World Health Organization (WHO) reference standard. One unit is approximately equivalent to amount of antithrombin III (mg) in 1 mL of pooled human plasma from healthy donors. Specific activity of antithrombin III is 6.9-9 units of antithrombin III per mg of protein.
Number of units of antithrombin III indicated on label of each vial.
Use clinical response and laboratory tests to guide dosage calculations. (See Laboratory Monitoring under Cautions.)
Determine preinfusion (baseline) antithrombin III concentration and calculate initial (loading) dosage using following formula:
Formula is based on expected incremental in vivo recovery (increase) of antithrombin III concentrations above baseline values of 1.4% for each unit/kg administered (functional activity).
For example, to increase antithrombin III plasma concentrations to 120% of normal from a baseline antithrombin III plasma concentration of 57% of normal, the total initial dose of antithrombin III for a 70-kg adult would be 3150 units.
Following initial dose, subsequent dose can be based on recovery (increase) of antithrombin III plasma concentrations resulting from initial dose. Base adjustments of maintenance dosage and/or dosage interval on actual antithrombin III plasma concentrations achieved.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
None known.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- Hemorrhage
- Thromboembolic disorder
Adverse reactions
Dizziness, chest tightness, nausea, foul taste, chills, cramps, shortness of breath, chest pain, film over eye, lightheadedness, bowel fullness, hives, fever, oozing, hematoma formation.
Rare or Very Rare
- Abdominal pain with cramps
- Chest tightness
- Chills
- Dizziness
- Dyspnea
- Fever
- Hematoma
- Urticaria
Rare or Very Rare
- Dysgeusia
- Nausea
Precautions
No enhanced messaging available.
Safety and efficacy of antithrombin III not established in pediatric patients younger than 16 years of age.
Fatal thromboembolism (e.g., aortic thrombi) reported in neonates born to women with congenital antithrombin III deficiency. Determine antithrombin III concentrations immediately after birth in neonates of parents with congenital antithrombin III deficiency.
Plasma antithrombin III concentrations in healthy full-term neonates or healthy premature neonates average approximately 60 or 35%, respectively, of those in healthy adults. Low antithrombin III plasma concentrations, especially in premature neonates, do not necessarily indicate congenital deficiency.
Manufacturer and some clinicians recommend consultation with an expert on coagulation disorders regarding testing and treatment of neonates with suspected congenital antithrombin III deficiency.
Category B. (See Users Guide.)
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Antithrombin III deficiency | ||
| D68.59 | ICD10CM | Other primary thrombophilia |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.